Galectin Therapeutics Seeks Shareholder Approval to Double Authorized Shares to 250M
GALT sits 95% above its 52-week low of $2.025 on light trading volume (0.3× avg).
Summary
Galectin Therapeutics' definitive proxy asks shareholders to approve a 100 million share increase in authorized common stock, from 150 million to 250 million, at the December 3, 2026 annual meeting.
Key Events · Corporate Governance and Compliance · GALT
-
Authorized Share Increase Proposed
Proposal 2 seeks to increase authorized common stock from 150,000,000 to 250,000,000 shares, adding 100 million shares for future issuance.
-
Equity Plan Expansion
Proposal 3 would reserve an additional 3,000,000 shares under the 2019 Omnibus Equity Incentive Plan, increasing the plan from 10,000,000 to 13,000,000 shares.
-
Annual Meeting Scheduled
The 2026 Annual Meeting will be held virtually on December 3, 2026, with a record date of October 6, 2026.
-
Chairman's 49.4% Stake
Richard Uihlein beneficially owns 54,831,388 shares, or 49.4% of common stock, after converting $105.8 million of debt to equity on July 31, 2026.
Analysis · GALT · Life Sciences
The definitive proxy sets a December 3, 2026 vote on increasing authorized common stock from 150 million to 250 million shares. With only about 26 million authorized shares remaining after accounting for outstanding instruments, the company states it needs flexibility for future equity financings to fund operations beyond the next twelve months. Chairman Richard Uihlein, who controls 49.4% of the stock, converted $105.8 million of debt to equity in July 2026, eliminating nearly all debt but leaving the company reliant on equity raises. The additional 100 million authorized shares represent potential future dilution for existing holders, though no immediate issuance is planned.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GALT was trading at $3.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $390.3M. The 52-week trading range was $2.03 to $7.13. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.